U
ARIA

UBS’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

UBS’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$572K Buy
105,900
+400
+0.4% +$2.34K ﹤0.01% 4125
2014
Q2 		$672K Buy
105,500
+82,900
+367% +$570K ﹤0.01% 3936
2014
Q1 		$182K Sell
22,600
-67,900
-75% -$529K ﹤0.01% 5301
2013
Q4 		$617K Buy
90,500
+83,500
+1,193% +$451K ﹤0.01% 4090
2013
Q3 		$129K Sell
7,000
-400
-5% -$7.77K ﹤0.01% 5728
2013
Q2 		$129K Buy
+7,400
New +$131K ﹤0.01% 5585

Other funds holding ARIA

SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

UBS's ARIA Position: Q3 2014 in Review

UBS increased its Ariad Pharmaceuticals Inc (ARIA) stake by 13% in Q3 2014, buying an estimated $243K and bringing the position to 368,956 shares worth $1.99M. The position accounts for ﹤0.01% of the portfolio, ranked #2916.

UBS first reported a position in ARIA in Q2 2013 and has held it in 6 quarters since. The position peaked at $4.42M in Q2 2013. 169 funds tracked by Wall St. Rank hold ARIA as of Q3 2014.

  • UBS held 368,956 shares of Ariad Pharmaceuticals Inc worth $1.99M as of Q3 2014.
  • UBS bought 41,677 Ariad Pharmaceuticals Inc shares in Q3 2014, an estimated $243K.
  • Ariad Pharmaceuticals Inc made up ﹤0.01% of UBS's portfolio in Q3 2014, its #2916 holding.
  • UBS first reported a position in Ariad Pharmaceuticals Inc in Q2 2013 and has held it in 6 quarters since.
  • UBS's Ariad Pharmaceuticals Inc position peaked at $4.42M in Q2 2013.
  • 169 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.